Valois acquires rights to new dry powder inhaler

Published: 10-Dec-2003


Valois Pharmaceutical Division, of France, has expanded its pulmonary franchise with the acquisition of intellectual property rights and equipment related to the Bead Inhaler from Quadrant Technologies, based in Nottingham in the UK.

'The technology is a novel multidose inhaler device under development based on a blister-type powder storage system which provides advanced moisture protection for the drug product and high fine particle fraction performance,' explained Olivier Fourment, President of Valois.

'This technology is a perfect complement to our metering valves used for pressurised metered dose inhalers. It will allow us to strengthen our leading position in pulmonary drug delivery devices and offer pharmaceutical and biotechnology companies a portfolio of technologies.'

Along with this technology deal, Valois Pharmaceutical Division has also secured the services of Quadrant Drug Delivery, a subsidiary of Quadrant Technologies, for the development of dry powder formulations suitable for this novel DPI device.

Dr Cheryl Rogerson, former programme director at Quadrant Drug Delivery has been appointed associate director responsible for the dry powder programme at Valois Pharmaceutical Division.

  

You may also like